Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2001 Feb;84(4):565–570. doi: 10.1054/bjoc.2000.1625

Electroporation of human microvascular endothelial cells: evidence for an anti-vascular mechanism of electrochemotherapy

M Cemazar 1,2, C S Parkins 2, A L Holder 2, D J Chaplin 2, G M Tozer 2, G Sersa 1
PMCID: PMC2363761  PMID: 11207055

Abstract

Recent studies have indicated that the antitumour effectiveness of electrochemotherapy, a combination of chemotherapeutic drugs with application of high voltage electric pulses applied to the tumour nodule (electroporation), result in a significant reduction in tumour blood flow and may therefore be mediated by an anti-vascular mechanism. The aim of this study was to evaluate the cytotoxicity of electroporation with bleomycin or cisplatin on cultured human microvascular endothelial cells (HMEC-1). The sensitivity of HMEC-1 cells to a 5 min treatment by electroporation with bleomycin or cisplatin (8 electric pulses, pulse duration 100 μs, frequency 1 Hz, electric field intensity 1400 V cm–1) was compared to the sensitivity of cells treated continuously for 3 days with drugs alone. HMEC-1 cells were moderately sensitive to continuous exposure to cisplatin, but showed greater sensitivity to bleomycin. Combination of a 5 min drug exposure with electric pulses increased cytotoxicity of cisplatin by ∼10-fold for cisplatin and ∼5000-fold for bleomycin. The electroporation of HMEC-1 cells with bleomycin for a 5 min exposure was ∼250-fold better than a continuous exposure to the drug alone. The results of this study indicate that the anti-tumour action of electrochemotherapy is likely to be due, in part, to the highly sensitive response of vascular endothelial cells. Further studies are necessary to identify the determinants of endothelial response and its relationship to the anti-vascular action of electrochemotherapy in vivo. © 2001 Cancer Research Campaign http://www.bjcancer.com

Keywords: endothelial cells, anti-vascular action, electrochemotherapy, electroporation, bleomycin, cisplatin

Full Text

The Full Text of this article is available as a PDF (216.8 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Acunaş B., Rozanes I. Hepatocellular carcinoma: treatment with transcatheter arterial chemoembolization. Eur J Radiol. 1999 Oct;32(1):86–89. doi: 10.1016/s0720-048x(99)00117-5. [DOI] [PubMed] [Google Scholar]
  2. Ades E. W., Candal F. J., Swerlick R. A., George V. G., Summers S., Bosse D. C., Lawley T. J. HMEC-1: establishment of an immortalized human microvascular endothelial cell line. J Invest Dermatol. 1992 Dec;99(6):683–690. doi: 10.1111/1523-1747.ep12613748. [DOI] [PubMed] [Google Scholar]
  3. Belehradek J., Jr, Orlowski S., Ramirez L. H., Pron G., Poddevin B., Mir L. M. Electropermeabilization of cells in tissues assessed by the qualitative and quantitative electroloading of bleomycin. Biochim Biophys Acta. 1994 Feb 23;1190(1):155–163. doi: 10.1016/0005-2736(94)90045-0. [DOI] [PubMed] [Google Scholar]
  4. Cemazar M., Miklavcic D., Scancar J., Dolzan V., Golouh R., Sersa G. Increased platinum accumulation in SA-1 tumour cells after in vivo electrochemotherapy with cisplatin. Br J Cancer. 1999 Mar;79(9-10):1386–1391. doi: 10.1038/sj.bjc.6690222. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Cemazar M., Miklavcic D., Sersa G. Intrinsic sensitivity of tumor cells to bleomycin as an indicator of tumor response to electrochemotherapy. Jpn J Cancer Res. 1998 Mar;89(3):328–333. doi: 10.1111/j.1349-7006.1998.tb00566.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Cemazar M., Sersa G., Miklavcic D. Electrochemotherapy with cisplatin in the treatment of tumor cells resistant to cisplatin. Anticancer Res. 1998 Nov-Dec;18(6A):4463–4466. [PubMed] [Google Scholar]
  7. Clements M. K., Jones C. B., Cumming M., Daoud S. S. Antiangiogenic potential of camptothecin and topotecan. Cancer Chemother Pharmacol. 1999;44(5):411–416. doi: 10.1007/s002800050997. [DOI] [PubMed] [Google Scholar]
  8. Denekamp J. Vascular attack as a therapeutic strategy for cancer. Cancer Metastasis Rev. 1990 Nov;9(3):267–282. doi: 10.1007/BF00046365. [DOI] [PubMed] [Google Scholar]
  9. Dirix L. Y., Libura M., Libura J., Vermeulen P. B., De Bruijn E. A., Van Oosterom A. T. In vitro toxicity studies with mitomycins and bleomycin on endothelial cells. Anticancer Drugs. 1997 Oct;8(9):859–868. doi: 10.1097/00001813-199710000-00007. [DOI] [PubMed] [Google Scholar]
  10. Gilbert R. A., Jaroszeski M. J., Heller R. Novel electrode designs for electrochemotherapy. Biochim Biophys Acta. 1997 Feb 11;1334(1):9–14. doi: 10.1016/s0304-4165(96)00119-5. [DOI] [PubMed] [Google Scholar]
  11. Hait W. N., Gesmonde J. F., Lazo J. S. Effect of anti-calmodulin drugs on the growth and sensitivity of C6 rat glioma cells to bleomycin. Anticancer Res. 1994 Sep-Oct;14(5A):1711–1721. [PubMed] [Google Scholar]
  12. Kambe M., Arita D., Kikuchi H., Funato T., Tezuka F., Gamo M., Murakawa Y., Kanamaru R. Enhancing the effect of anticancer drugs against the colorectal cancer cell line with electroporation. Tohoku J Exp Med. 1996 Oct;180(2):161–171. doi: 10.1620/tjem.180.161. [DOI] [PubMed] [Google Scholar]
  13. Kuriyama S., Matsumoto M., Mitoro A., Tsujinoue H., Toyokawa Y., Nakatani T., Yamazaki M., Okamoto S., Fukui H. Electrochemotherapy against colorectal carcinoma: comparison of in vitro cytotoxicity of 5-fluorouracil, cisplatin and bleomycin. Int J Oncol. 1999 Jul;15(1):89–94. doi: 10.3892/ijo.15.1.89. [DOI] [PubMed] [Google Scholar]
  14. Lazo J. S., Braun I. D., Labaree D. C., Schisselbauer J. C., Meandzija B., Newman R. A., Kennedy K. A. Characteristics of bleomycin-resistant phenotypes of human cell sublines and circumvention of bleomycin resistance by liblomycin. Cancer Res. 1989 Jan 1;49(1):185–190. [PubMed] [Google Scholar]
  15. Miklavcic D., Beravs K., Semrov D., Cemazar M., Demsar F., Sersa G. The importance of electric field distribution for effective in vivo electroporation of tissues. Biophys J. 1998 May;74(5):2152–2158. doi: 10.1016/S0006-3495(98)77924-X. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Mir L. M., Roth C., Orlowski S., Quintin-Colonna F., Fradelizi D., Belehradek J., Jr, Kourilsky P. Systemic antitumor effects of electrochemotherapy combined with histoincompatible cells secreting interleukin-2. J Immunother Emphasis Tumor Immunol. 1995 Jan;17(1):30–38. doi: 10.1097/00002371-199501000-00004. [DOI] [PubMed] [Google Scholar]
  17. Orlowski S., Belehradek J., Jr, Paoletti C., Mir L. M. Transient electropermeabilization of cells in culture. Increase of the cytotoxicity of anticancer drugs. Biochem Pharmacol. 1988 Dec 15;37(24):4727–4733. doi: 10.1016/0006-2952(88)90344-9. [DOI] [PubMed] [Google Scholar]
  18. Rols M. P., Teissié J. Flow cytometry quantification of electropermeabilization. Methods Mol Biol. 1998;91:141–147. doi: 10.1385/0-89603-354-6:141. [DOI] [PubMed] [Google Scholar]
  19. Sersa G., Cemazar M., Menart V., Gaberc-Porekar V., Miklavcic D. Anti-tumor effectiveness of electrochemotherapy with bleomycin is increased by TNF-alpha on SA-1 tumors in mice. Cancer Lett. 1997 Jun 3;116(1):85–92. doi: 10.1016/s0304-3835(97)00170-5. [DOI] [PubMed] [Google Scholar]
  20. Sersa G., Cemazar M., Miklavcic D. Antitumor effectiveness of electrochemotherapy with cis-diamminedichloroplatinum(II) in mice. Cancer Res. 1995 Aug 1;55(15):3450–3455. [PubMed] [Google Scholar]
  21. Sersa G., Cemazar M., Miklavcic D., Chaplin D. J. Tumor blood flow modifying effect of electrochemotherapy with bleomycin. Anticancer Res. 1999 Sep-Oct;19(5B):4017–4022. [PubMed] [Google Scholar]
  22. Sersa G., Cemazar M., Parkins C. S., Chaplin D. J. Tumour blood flow changes induced by application of electric pulses. Eur J Cancer. 1999 Apr;35(4):672–677. doi: 10.1016/s0959-8049(98)00426-2. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES